This article summarized the latest R&D progress of methsuximide, the Mechanism of Action for methsuximide, and the drug target R&D trends for methsuximide.

Despite Novartis being a consistent top contender in the pharmaceutical sector in terms of revenue, its growth and market value in recent years has been rather dismal.

Androgen receptor (AR) is a type of nuclear receptor that is activated by binding of either of the androgenic hormones testosterone or dihydrotestosterone in the cytoplasm and then translocating into the nucleus.

In conjunction with Zealand Pharma A/S, Boehringer Ingelheim has initiated three Phase III research investigations for survodutide (also known as BI 456906)

This article summarized the latest R&D progress of methyclothiazide, the Mechanism of Action for methyclothiazide, and the drug target R&D trends for methyclothiazide.

AstraZeneca has shown a steady performance in the past two years, and its market value has effectively stabilized at over 200 billion.

This article summarized the latest R&D progress of ingenol mebutate, the Mechanism of Action for ingenol mebutate, and the drug target R&D trends for ingenol mebutate.

First patient administered by Tenaya Therapeutics in MyPeak-1™ Phase 1b Clinical Trial for TN-201 treatment to address MYBPC3-Associated Hypertrophic Cardiomyopathy.

Janus kinase inhibitor, often referred to as JAKi, is a type of oral small molecule chemically synthesized drug.

The Swiss pharmaceutical giant Roche has seen sluggish growth in its oncology division, with almost no increase in four years, worsened further by the weakening of the diagnostic division due to the COVID-19 pandemic.

This article summarized the latest R&D progress of inositol nicotinate, the Mechanism of Action for inositol nicotinate, and the drug target R&D trends for inositol nicotinate.

Oncternal Therapeutics starts administrating the first dose in phase 1/2 trial of ONCT-534, a dual-action AR inhibitor, for metastatic castration-resistant prostate cancer patients.